Table 4.
Haplotypeb | Multivitamin non-users |
Multivitamin users |
All subjects |
||||||
---|---|---|---|---|---|---|---|---|---|
Global haplotype test P value | Estimated haplotype frequency | OR (95% CI) | Global haplotype test P value | Estimated haplotype frequency | OR (95% CI) | Global haplotype test P value | Estimated haplotype frequency | OR (95% CI) | |
0.56 | 0.01 | 0.70 | |||||||
001101000 | 0.26 | 1.04 (0.86–1.26) | 0.24 | 0.76 (0.59–0.97) | 0.25 | 0.93 (0.81–1.07) | |||
010000001 | 0.26 | 0.98 (0.81–1.19) | 0.25 | 0.82 (0.65–1.04) | 0.26 | 0.94 (0.82–1.08) | |||
100001011 | 0.05 | 1.23 (0.84–1.79) | 0.05 | 0.74 (0.46–1.19) | 0.05 | 1.05 (0.80–1.38) | |||
000101000 | 0.07 | 1.16 (0.89–1.51) | 0.07 | 0.96 (0.68–1.35) | 0.06 | 1.01 (0.82–1.23) | |||
100010000 | 0.10 | 0.73 (0.55–0.98) | 0.10 | 1.10 (0.78–1.55) | 0.10 | 0.95 (0.78–1.16) | |||
101001011 | 0.01 | 0.69 (0.29–1.66) | 0.02 | 1.28 (0.53–3.05) | 0.01 | 0.77 (0.42–1.40) | |||
101010000 | 0.02 | 1.13 (0.63–2.03) | 0.03 | 1.50 (0.79–2.87) | 0.02 | 1.17 (0.78–1.75) | |||
000000100 | 0.03 | 0.87 (0.56–1.38) | 0.03 | 1.52 (0.90–2.56) | 0.03 | 1.02 (0.73–1.43) | |||
001000100 | 0.13 | 1.00 (0.78–1.29) | 0.13 | 1.39 (1.04–1.87) | 0.13 | 1.16 (0.97–1.38) | |||
011000001 | 0.06 | 1.07 (0.79–1.45) | 0.08 | 1.42 (1.04–1.95) | 0.06 | 1.12 (0.91–1.39) |
aAdjusted for age (<40, 40–49, 50–59, 60–69, and 70+ yrs), residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota, South Dakota, and North Carolina), body mass index, age at menarche, oral contraceptive use, postmenopausal status, postmenopausal hormone use, parity/age at first birth, smoking, and education (see Table 1 for categories). Haplotype associations were estimated using log-additive logistic regression models.
bEstimated using both cases and controls; SNPs that formed ATIC haplotypes were, in positional order, rs3772078, rs2372536, rs1880586, rs1983462, rs16853826, rs7586969, rs16853834, rs1404772, rs7604984, where 0 = common allele and 1 = rare allele. Bold indicates the two significant SNPs with opposing effects from Table 3.